Meiragtx Holdings(MGTX)
$8.32-0.14 (-1.65%)
MGTX
Meiragtx Holdings stock drug pipeline
$8.32
At close:-0.14 (-1.65%)
Want to see MGTX full AI Analyst Report?
Meiragtx Holdings (MGTX) Drug Pipeline
540 Followers
| Drug Name | Condition | Stage | Status | Study Name | Trial Start Date | Article |
|---|---|---|---|---|---|---|
| Aav2-Haqp1 | Grade 2 And 3 Late Xerostomia Caused By Radiotherapy For Cancers Of The Upper Aerodigestive Tract, Excluding The Parotid Glands | Phase II | Enrolling By Invitation | Long-term Follow-up of Gene Therapy for Radiation-Induced Xerostomia | Aug 05, 2024 | ― |
| Aav2-Haqp1 Concentration 1, Aav2-Haqp1 Concentration 2, Aav2-Haqp1 Concentration 3, Aav2-Haqp1 Concentration 4 | Grade 2 And 3 Late Xerostomia Caused By Radiotherapy For Cancers Of The Upper Aerodigestive Tract, Excluding The Parotid Glands | Phase II | Recruiting | A Study of AAV2-hAQP1 Gene Therapy in Participants With Radiation-Induced Late Xerostomia | Jun 22, 2023 | ― |
| Aav-Gad | Parkinson's Disease | phase1AndPhase2 | Active Not Recruiting | Long-term Follow-up of Glutamic Acid Decarboxylase (GAD) Gene Transfer in Parkinson's Disease | May 30, 2023 | ― |
| Aav-Gad Low Dose, Aav-Gad High Dose, Sham Surgery | Parkinson's Disease | phase1AndPhase2 | Completed | A Double-blind Study to Evaluate the Safety of Glutamic Acid Decarboxylase Gene Transfer in Parkinson's Participants | Oct 12, 2022 | ― |
| Aav2haqp1 | Squamous Cell Head And Neck Cancer, Radiation Induced Xerostomia, Salivary Hypofunction | Phase I | Active Not Recruiting | Safety of a Single Administration of AAV2hAQP1, an Adeno-Associated Viral Vector Encoding Human Aquaporin-1 to One Parotid Salivary Gland in People With Irradiation-Induced Parotid Salivary Hypofunction | May 14, 2015 | ― |
| Drug Name | Stage | Condition | Status | Study Name | Trial Start Date | Article |
|---|---|---|---|---|---|---|
| Aav2-Haqp1 | Phase II | Grade 2 And 3 Late Xerostomia Caused By Radiotherapy For Cancers Of The Upper Aerodigestive Tract, Excluding The Parotid Glands | Enrolling By Invitation | Long-term Follow-up of Gene Therapy for Radiation-Induced Xerostomia | Aug 05, 2024 | ― |
| Aav2-Haqp1 Concentration 1, Aav2-Haqp1 Concentration 2, Aav2-Haqp1 Concentration 3, Aav2-Haqp1 Concentration 4 | Phase II | Grade 2 And 3 Late Xerostomia Caused By Radiotherapy For Cancers Of The Upper Aerodigestive Tract, Excluding The Parotid Glands | Recruiting | A Study of AAV2-hAQP1 Gene Therapy in Participants With Radiation-Induced Late Xerostomia | Jun 22, 2023 | ― |
| Aav-Gad | phase1AndPhase2 | Parkinson's Disease | Active Not Recruiting | Long-term Follow-up of Glutamic Acid Decarboxylase (GAD) Gene Transfer in Parkinson's Disease | May 30, 2023 | ― |
| Aav-Gad Low Dose, Aav-Gad High Dose, Sham Surgery | phase1AndPhase2 | Parkinson's Disease | Completed | A Double-blind Study to Evaluate the Safety of Glutamic Acid Decarboxylase Gene Transfer in Parkinson's Participants | Oct 12, 2022 | ― |
| Aav2haqp1 | Phase I | Squamous Cell Head And Neck Cancer, Radiation Induced Xerostomia, Salivary Hypofunction | Active Not Recruiting | Safety of a Single Administration of AAV2hAQP1, an Adeno-Associated Viral Vector Encoding Human Aquaporin-1 to One Parotid Salivary Gland in People With Irradiation-Induced Parotid Salivary Hypofunction | May 14, 2015 | ― |
FAQ
What are the FDA phases for drug approval?
The FDA approval process for new drugs is divided into several phases: a. Preclinical testing b. Phase 1 – Safety and dosage c. Phase 2 – Effectiveness and side effects d. Phase 3 – Confirmation of effectiveness, monitoring of adverse reactions, and comparison with existing treatments e. Phase 4 – Post-marketing studies to track long-term safety and effectiveness
What is a clinical trial?
A clinical trial is a carefully designed study in which researchers test a drug, treatment, or medical device in people to evaluate its safety, effectiveness, and potential side effects. These trials are essential for determining whether a new treatment should be approved for widespread use.
What drugs does Meiragtx Holdings (MGTX) have in its pipeline
Meiragtx Holdings MGTX is currently developing the following drugs: Aav2-Haqp1, Aav2-Haqp1 Concentration 1, Aav2-Haqp1 Concentration 2, Aav2-Haqp1 Concentration 3, Aav2-Haqp1 Concentration 4, Aav-Gad, Aav-Gad Low Dose, Aav-Gad High Dose, Sham Surgery, Aav2haqp1. These drug candidates are in various stages of clinical development as the company works toward FDA approval.

